Shares of Opko Health Inc. (NYSE:OPK) ended Friday session in green amid volatile trading. The shares closed up +0.16 points or 1.75% at $9.30 with 2.70M shares getting traded. Post opening the session at $9.17, the shares hit an intraday low of $9.01 and an intraday high of $9.38 and the price vacillated in this range throughout the day.
The 52-week high of (OPK) is $19.20 and the 52-week low is $7.12. The stock’s 50 day moving average price is $8.27 and its 200 day moving average price is $9.80.
Company’s sales growth for the past five years is valued at 83.30%, leading it to the existing share price of 9.31 and a target price of 17.20.
Market Cap/Outstanding Shares
The company has a market cap of $5.16 billion and the numbers of outstanding shares have been calculated to be 545.01 million shares.
Performance weekly/monthly/quarterly/yearly in percentage (%)
The performance for the week is valued at 5.56%, resulting in a performance for the month at 18.45%. Therefore, the stated figure displays a quarterly performance of -14.11% and an annual performance of -37.26% traded up 1.75% on 26 February, hitting $9.31.
EPS (Earning Per Share)
The EPS of OPK is strolling at -0.23, measuring its EPS growth this year at -28.10%. As a result, the company has an EPS growth of 142.90% for the approaching year. Company’s EPS for the past five years is valued at -27.90%, leading it to an EPS value of 0.00% for the next five years.
P/S—P/B—P/C—P/FCF
Opko Health Inc. has a P/S value of 21.05, measuring P/B at 2.36. Its P/Cash is valued at 23.92 and P/FCF is at 36.72.
Gross margin/Profit Margin/Gross Profit
The company’s gross margin is 56.90%. And Profit margin of OPK is -35.10% with gross profit $43.12 million.
Beta/ATR/Volatility
Beta factor stands at 1.44 and Avg. true range is 0.46. Historically, the volatility of this stock is about 3.94% a week and 5.52% a month.
Opko Health Inc. (OPK) announced that it will release operating and financial results for the three and 12 months ended December 31, 2015 after the close of the U.S. financial markets on Monday, February 29, 2016.
OPKO’s senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Monday, February 29, 2016.
CONFERENCE CALL & WEBCAST INFORMATION
WHEN: Monday, February 29, 2016, 4:30 p.m. Eastern time
DOMESTIC DIAL-IN: (866) 634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454
PASSCODE: 56397388
WEBCAST: www.opko.com
For those unable to participate in the live conference call or webcast, a replay will be available beginning February 29, 2016 at 7:30 p.m. Eastern time. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 56397388. The replay can also be accessed for a period of time on OPKO’s website
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. The company develops various solutions to diagnose, treat, and prevent various conditions, including point-of-care tests, molecular diagnostics tests, laboratory developed tests, and proprietary pharmaceuticals and vaccines. Its products include 4Kscore test that measures the blood plasma levels of four different prostate-derived kallikrein proteins. The companys lead product candidates comprise Rayaldee to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Alpharen to treat hyperphosphatemia in stage 5 patients on chronic hemodialysis. It is also developing CTP, hGH-CTP for the treatment of growth hormone deficiency; Factor VII-CTP for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX; Inspiromatic, a powder inhaler for use in the therapy for asthma, chronic obstructive pulmonary disease, cystic fibrosis, and other respiratory diseases; and rolapitant for the prevention of chemotherapy induced nausea and vomiting, as well as focuses on the development of a long-acting oxyntomdulinGLP-1/glucagon dual receptor agonist. In addition, the company is developing Claros1 immunoassay instrument system that provides rapid blood test results and enables complex tests to be run in point-of-care settings; drugs for the treatment cancer, heart disease, metabolic disorders, and various genetic anomalies; and has various therapeutic agents in clinical development for the treatment of respiratory disorders. Further, it operates a full-service medical laboratory specializing in urologic pathology. OPKO Health, Inc. is based in Miami, Florida.
For more info visit Website: http://www.opko.com